AstraZeneca has made a sizeable play in applying artificial intelligence to drug discovery in its rare disease unit Alexion, partnering with Verge Genomics in a deal that
AstraZeneca's Soliris has become the first approved treatment in the EU for children and adolescents with generalised myasthenia gravis, a disorder that causes weakness in
Novartis has a second positive phase 3 trial in the bag for its targeted factor B inhibitor iptacopan, vying to become an oral alternative to injectable therapies for ultra-rare blood disor
Novartis has chalked up another clinical trial win for its targeted factor B inhibitor iptacopan as it strives to position the drug as a patient-friendly, oral alternative to big-selling in
AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately
Amgen’s famously voracious legal team is living up to its reputation once again, this time with a surprise challenge on the patents surrounding Alexion’s rare diseases blockbuster, Soliris.
US retailer Costco has made a play for a bigger slice of the healthcare market by offering its members online health visits, starting from just $29, as well as other servi
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho